Loureirin A

CAS# 119425-89-7

Loureirin A

Catalog No. BCN3671----Order now to get a substantial discount!

Product Name & Size Price Stock
Loureirin A: 5mg $115 In Stock
Loureirin A: 10mg Please Inquire In Stock
Loureirin A: 20mg Please Inquire Please Inquire
Loureirin A: 50mg Please Inquire Please Inquire
Loureirin A: 100mg Please Inquire Please Inquire
Loureirin A: 200mg Please Inquire Please Inquire
Loureirin A: 500mg Please Inquire Please Inquire
Loureirin A: 1000mg Please Inquire Please Inquire

Quality Control of Loureirin A

Number of papers citing our products

Chemical structure

Loureirin A

3D structure

Chemical Properties of Loureirin A

Cas No. 119425-89-7 SDF Download SDF
PubChem ID 5319081 Appearance White powder
Formula C17H18O4 M.Wt 286.3
Type of Compound Chalcones Storage Desiccate at -20°C
Synonyms 4'-Hydroxy 2,4-dimethoxydihydrochalcone
Solubility DMSO : ≥ 86.6 mg/mL (302.46 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 3-(2,4-dimethoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one
SMILES COC1=CC(=C(C=C1)CCC(=O)C2=CC=C(C=C2)O)OC
Standard InChIKey RSAIVLRELNGZEY-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H18O4/c1-20-15-9-5-13(17(11-15)21-2)6-10-16(19)12-3-7-14(18)8-4-12/h3-5,7-9,11,18H,6,10H2,1-2H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Loureirin A

The herbs of Dracaena cochinchinensis

Biological Activity of Loureirin A

DescriptionLoureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling. Loureirin A activates Wnt/-catenin pathway and promotes hair follicle stem cells (FSCs)-seeded tissue-engineered skin to repair skin wound.The molecular mechanism of Loureirin A and Wnt signaling pathway mediated anti- hepatic fibrosis and anti- angiogenesis may involve down- regulation the expression of Frizzled- 4,inhibiting the synthesis and secretion of α- SMA,TGF- β1and the proliferation of HSCs.
TargetsAkt | PI3K | c-Myc | GSK-3 | Wnt/β-catenin | TGF-β/Smad | Frizzled- 4
In vitro

Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies.[Pubmed: 25445049]

Eur J Pharmacol. 2015 Jan 5;746:63-9.

Loureirin A is a flavonoid extracted from Dragon׳s Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood.
METHODS AND RESULTS:
We explored the anti-platelet activity and underlying mechanism of Loureirin A in vitro. Our results indicated that Loureirin A negatively affected agonist-induced platelet aggregation such as collagen, collagen-related peptide (CRP), ADP and thrombin. Loureirin A inhibited collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Platelet spreading on immobilized fibrinogen was significantly impaired in the presence of Loureirin A. Immunoblotting analysis indicated that 100μM of Loureirin A almost completely eliminated collagen-induced Akt phosphorylation at Ser473. Interestingly, a submaximal dose (50μM) of Loureirin A had an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets.
CONCLUSIONS:
Taken together, Loureirin A had an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.

Effect of Loureirin A on Proliferation and Frizzled-4Expression of Rat Hepatic Stellate Cells in vitro[Reference: WebLink]

Journal of Kunming Medical University, 2016 , 37 (6) :13-17.

To investigate the molecular mechanism of Loureirin A mediated anti- hepatic fibrosis by evaluting its effects on proliferation,secretion of α- smooth muscle actin(α- SMA) and transforming growth factor- beta1(TGF- β1), and expression of rat hepatic stellate cells in vitro.
METHODS AND RESULTS:
Primary hepatic stellate cells were isolated and cultured from Sprague- Dawley rats. After activating and inducing primary hepatic stellate cells from q HSC to a HSC, the activated hepatic stellate cells model in vitro was established. Then we observed the morphological changes of static hepatic stellate cells and activated hepatic stellate cells with inverted phase contrast microscope. Cultured hepatic stellate cells were treated with different concentrations of Loureirin A and the inhibitory rate of HSCs proliferation was measured by MTT assay. The expression of Frizzled- 4 was measured by western blot analysis. The content of α- SMA and TGF- β1 in the cultured HSCs' supernatant were measured by enzyme- linked immunosorbent assay(ELISA). Loureirin A the proliferation of inhibited activated hepatic stellate cells in a time- dose- dependent manner compared with the control group,IC50=0.30 μg/μL. After Loureirin A treatment of the HSCs, western blot analysis showed that Frizzled- 4 expression level was obviously lower than control group.Loureirin A also inhibited α- SMA and TGFβ1(P0.05) secretion in the cultured HSCs' supernatant in different degree by the assay of ELISA.
CONCLUSIONS:
The molecular mechanism of Loureirin A and Wnt signaling pathway mediated anti- hepatic fibrosis and anti- angiogenesis may involve down- regulation the expression of Frizzled- 4,inhibiting the synthesis and secretion of α- SMA,TGF- β1and the proliferation of HSCs.

Protocol of Loureirin A

Animal Research

Loureirin A Activates Wnt/β-Catenin Pathway to Promote Wound with Follicle Stem Cell-Seeded Tissue-Engineered Skin Healing[Reference: WebLink]

Journal of Biomaterials & Tissue Engineering, 2016 , 6 (6) :427-432.

Hair follicle stem cells (FSCs) can participate in the formation of hair follicles and epidermis. FSCs are well known as the ideal seed cells for tissue-engineered skin. Loureirin A, the major constituent of resina draconis, can promote skin wound healing.
METHODS AND RESULTS:
In this study, FSCs and hair follicle fibroblasts were combined with Pelnac® scaffold to construct tissue-engineered skin. The tissue-engineered skin was grafted into full-thickness skin defects of BALB/c-nu mice. Loureirin A was incorporated into the transplanted tissue-engineered skin. On day 3 of post-transplantation, Loureirin A could inhibit inflammatory reaction. On day 7 of post-transplantation, Loureirin A promoted the fibroblasts proliferation to repair dermis, and the newly formed epidermis was thicker than normal epidermis. On day 14 of post-transplantation, Loureirin A promoted the newly formed skin tending to the normal skin. All of these results showed that Loureirin A could promote skin wound repair. Wnt/β-catenin pathway controls natural hair follicle regeneration and epidermis' repairing on skin injuries. In order to validate whether Wnt/β-catenin pathway can be activated by Loureirin A, it was used to stimulate FSCs in vitro. The results displayed that Loureirin A could promote FSCs proliferation and change the cell cycle. Western blot showed that GSK-3β was down-regulated and β-catenin was up-regulated in FSCs by Loureirin A. Simultaneously, downstream genes of Wnt/β-catenin pathway, c-Myc, cyclin D1, Tcf3 and Lef1, also increased.
CONCLUSIONS:
Overall, these results demonstrate that Loureirin A activates Wnt/β-catenin pathway and promotes FSC-seeded tissue-engineered skin to repair skin wound.

Structure Identification
Eur J Med Chem. 2015 Mar 26;93:492-500.

Comparison between loureirin A and cochinchinenin C on the interaction with human serum albumin.[Pubmed: 25734332]


METHODS AND RESULTS:
The interactions of Loureirin A (LA) and cochinchinenin C (CC) with human serum albumin (HSA) under simulated physiological conditions (pH = 7.4) have been studied with fluorescence, UV-vis absorption spectroscopic method and molecular docking technique. The results indicated that there was a synergistic interaction between LA and CC, and the fluorescence quenching of HSA by LA (or CC) was a combined quenching procedure (dynamic and static quenching). At low compound concentrations, the quenching constants KSV of CC was larger than that of LA, which meant the CC efficacy may be better than that of LA. The negative △H and △S values suggested hydrogen bonds and van der Waals forces played the major role in the binding of LA (or CC) to HSA. The efficiency of energy transfer and distance between the compounds and HSA was calculated.
CONCLUSIONS:
Moreover, the results of synchronous and three-dimensional fluorescence demonstrated that the HSA microenvironment was changed in the presence of LA (or CC). Finally, the binding of LA (or CC) to HSA was modeled by molecular docking, which is in good accordance with the experimental studies.

Loureirin A Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Loureirin A Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Loureirin A

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.4928 mL 17.4642 mL 34.9284 mL 69.8568 mL 87.321 mL
5 mM 0.6986 mL 3.4928 mL 6.9857 mL 13.9714 mL 17.4642 mL
10 mM 0.3493 mL 1.7464 mL 3.4928 mL 6.9857 mL 8.7321 mL
50 mM 0.0699 mL 0.3493 mL 0.6986 mL 1.3971 mL 1.7464 mL
100 mM 0.0349 mL 0.1746 mL 0.3493 mL 0.6986 mL 0.8732 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Loureirin A

Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.

In Vitro:Loureirin A (50 μM, 100 μM) inhibits collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Loureirin A also significantly impairs platelet spreading on immobilized fibrinogen. Loureirin A almost completely eliminates collagen-induced Akt phosphorylation at Ser473 at the dose of 100 μM, and has an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets at 50 μM[1].

References:
[1]. Hao HZ, et al. Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies. Eur J Pharmacol. 2015 Jan 5;746:63-9.

Featured Products
New Products
 

References on Loureirin A

Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies.[Pubmed:25445049]

Eur J Pharmacol. 2015 Jan 5;746:63-9.

Loureirin A is a flavonoid extracted from Dragons Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood. We explored the anti-platelet activity and underlying mechanism of Loureirin A in vitro. Our results indicated that Loureirin A negatively affected agonist-induced platelet aggregation such as collagen, collagen-related peptide (CRP), ADP and thrombin. Loureirin A inhibited collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Platelet spreading on immobilized fibrinogen was significantly impaired in the presence of Loureirin A. Immunoblotting analysis indicated that 100muM of Loureirin A almost completely eliminated collagen-induced Akt phosphorylation at Ser473. Interestingly, a submaximal dose (50muM) of Loureirin A had an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets. Taken together, Loureirin A had an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.

Comparison between loureirin A and cochinchinenin C on the interaction with human serum albumin.[Pubmed:25734332]

Eur J Med Chem. 2015 Mar 26;93:492-500.

The interactions of Loureirin A (LA) and cochinchinenin C (CC) with human serum albumin (HSA) under simulated physiological conditions (pH = 7.4) have been studied with fluorescence, UV-vis absorption spectroscopic method and molecular docking technique. The results indicated that there was a synergistic interaction between LA and CC, and the fluorescence quenching of HSA by LA (or CC) was a combined quenching procedure (dynamic and static quenching). At low compound concentrations, the quenching constants KSV of CC was larger than that of LA, which meant the CC efficacy may be better than that of LA. The negative big up tri, openH and big up tri, openS values suggested hydrogen bonds and van der Waals forces played the major role in the binding of LA (or CC) to HSA. The efficiency of energy transfer and distance between the compounds and HSA was calculated. Moreover, the results of synchronous and three-dimensional fluorescence demonstrated that the HSA microenvironment was changed in the presence of LA (or CC). Finally, the binding of LA (or CC) to HSA was modeled by molecular docking, which is in good accordance with the experimental studies.

Description

Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.

Keywords:

Loureirin A,119425-89-7,4'-Hydroxy 2,4-dimethoxydihydrochalcone,Natural Products, buy Loureirin A , Loureirin A supplier , purchase Loureirin A , Loureirin A cost , Loureirin A manufacturer , order Loureirin A , high purity Loureirin A

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: